Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

Witty will act as a senior advisor to his successor, Stephen Hemsley, who served as UnitedHealth Group’s CEO from 2006 to ...

Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.

More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares opened today at p1 ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...